



# Rajasthan Medical Services Corporation Limited

Gandhi Block, Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066 , 2228064 Fax No. 0141-2228065 Website: <http://rmsc.health.rajasthan.gov.in>

CIN:U24232RJ2011SGC035067

E\_mail : [edprocurement@gmail.com](mailto:edprocurement@gmail.com), and [rmsc@nic.in](mailto:rmsc@nic.in)

Ref. No.:- F.02(215)/RMSC/PROCUREMENT/DRUG/NIB-18/2016/1561

Dated: 23.12.16

## Corrigendum - 1

**Subject:- Amendments in technical specifications and conditions.**


**Bid Ref. - F.02(215)/RMSC/PROCUREMENT/DRUG/NIB-18/2016/1469 Dated:01.12.2016  
(Technical bid opening due on dated - 24.11.2016)**

S. No	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.).																
1.	<p><b>Date of submission for E-bids reference no F.02(215)/RMSC/PROCUREMENT/DRUG/NIB-18/2016/1469 Dated:01.12.2016 is 1.30 PM of 03.01.2017</b></p> <table border="1"> <tr> <td>Last date and time of submission of online bids</td> <td>03.01.2017 at 1.30 PM</td> </tr> <tr> <td>Date and time of opening of Online technical bids</td> <td>03.01.2017 at 2.30 PM</td> </tr> <tr> <td>EMD, Tender fees, RISL fees through challan</td> <td>02.01.2017</td> </tr> <tr> <td>EMD, Tender fees, RISL fees Physically</td> <td>03.01.2017 at 1.30 PM</td> </tr> </table>	Last date and time of submission of online bids	03.01.2017 at 1.30 PM	Date and time of opening of Online technical bids	03.01.2017 at 2.30 PM	EMD, Tender fees, RISL fees through challan	02.01.2017	EMD, Tender fees, RISL fees Physically	03.01.2017 at 1.30 PM	<p><b>Date Extended for submission of E-bids reference noF.02(215)/RMSC/PROCUREMENT/DRUG/NIB-18/2016/1469 Dated:01.12.2016 is 1.30 PM of 06.01.2017</b></p> <table border="1"> <tr> <td>Last date and time of submission of online bids</td> <td>06.01.2017 up to 1.30 PM</td> </tr> <tr> <td>Date and time of opening of Online technical bids</td> <td>06.01.2017 at 2.30 PM</td> </tr> <tr> <td>EMD, Tender fees, RISL fees through challan</td> <td>05.01.2017</td> </tr> <tr> <td>EMD, Tender fees, RISL fees Physically</td> <td>06.01.2017 up to 1.30 PM</td> </tr> </table>	Last date and time of submission of online bids	06.01.2017 up to 1.30 PM	Date and time of opening of Online technical bids	06.01.2017 at 2.30 PM	EMD, Tender fees, RISL fees through challan	05.01.2017	EMD, Tender fees, RISL fees Physically	06.01.2017 up to 1.30 PM
Last date and time of submission of online bids	03.01.2017 at 1.30 PM																	
Date and time of opening of Online technical bids	03.01.2017 at 2.30 PM																	
EMD, Tender fees, RISL fees through challan	02.01.2017																	
EMD, Tender fees, RISL fees Physically	03.01.2017 at 1.30 PM																	
Last date and time of submission of online bids	06.01.2017 up to 1.30 PM																	
Date and time of opening of Online technical bids	06.01.2017 at 2.30 PM																	
EMD, Tender fees, RISL fees through challan	05.01.2017																	
EMD, Tender fees, RISL fees Physically	06.01.2017 up to 1.30 PM																	
2.	<p><b>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID Annexure-XV Ref. Clause No. 2 (c)</b></p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>160</td> <td>Levodopa and Carbidopa Tablets IP [Levodopa 100mg + Carbidopa 10 mg]</td> </tr> <tr> <td>211</td> <td>Verapamil Tablets IP 40 mg (Film Coated)</td> </tr> <tr> <td>282</td> <td>Clomifene Tablets IP 25 mg</td> </tr> </tbody> </table>	Code No.	Name of item with specification	160	Levodopa and Carbidopa Tablets IP [Levodopa 100mg + Carbidopa 10 mg]	211	Verapamil Tablets IP 40 mg (Film Coated)	282	Clomifene Tablets IP 25 mg	<p><b>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID Annexure-XV Ref. Clause No. 2 (c)</b></p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Relaxation in Condition of Market Standing Certificate and Performance Statement</th> </tr> </thead> <tbody> <tr> <td>160*</td> <td>Market Standing Certificate and performance statement of any tablet for one year acceptable.</td> </tr> <tr> <td>211*</td> <td>Market Standing Certificate and performance statement of any tablet for one year acceptable.</td> </tr> <tr> <td>282*</td> <td>Market Standing Certificate and performance statement of any tablet for one year acceptable.</td> </tr> </tbody> </table> <p>*However, for all above items, the firm has to submit with bid, the product permission (from the Licensing Authority) same as per bid specifications.</p>	Code No.	Relaxation in Condition of Market Standing Certificate and Performance Statement	160*	Market Standing Certificate and performance statement of any tablet for one year acceptable.	211*	Market Standing Certificate and performance statement of any tablet for one year acceptable.	282*	Market Standing Certificate and performance statement of any tablet for one year acceptable.
Code No.	Name of item with specification																	
160	Levodopa and Carbidopa Tablets IP [Levodopa 100mg + Carbidopa 10 mg]																	
211	Verapamil Tablets IP 40 mg (Film Coated)																	
282	Clomifene Tablets IP 25 mg																	
Code No.	Relaxation in Condition of Market Standing Certificate and Performance Statement																	
160*	Market Standing Certificate and performance statement of any tablet for one year acceptable.																	
211*	Market Standing Certificate and performance statement of any tablet for one year acceptable.																	
282*	Market Standing Certificate and performance statement of any tablet for one year acceptable.																	

3.	Annexure VIII and BoQ		Annexure VIII and BoQ	
	Code No.	Name of item with specification	Code No.	Name of item with specification
	227	Anti DRH Blood Grouping Serum IP	227	Anti D (Rh) Blood Grouping Serum IP / Anti D Blood Grouping Serum IP

**Note:-**

- It may be noted that if any type of amendments required than further corrigendum will be published and informed.
- Rest terms and conditions will remain the same.



 23.12.2016  
**Executive Director (Proc.)**  
**RMSC**